From the publishers of JADPRO

DLBCL Resource Center


Safety and efficacy of subcutaneous rituximab in previously untreated patients with CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from an Italian phase IIIb study

According to results of a phase 3b study of patients with CD20+ DLBCL or follicular lymphoma, switching from intravenous to subcutaneous rituximab was associated with a low risk of administration-related reactions and satisfactory response. Only 2 patients with DLBCL (2.8%) discontinued rituximab due to treatment-related adverse events, and 65.2% and 69.7% of patients with DLBCL had complete response (CR) and CR unconfirmed, respectively. At a median follow-up of 29.5 months, EFS, PFS, and OS were 70.8%, 70.8%, and 80.6% in patients with DLBCL, respectively.

Advances in Hematology
News & Literature Highlights

Medpage Today

New antibody-drug conjugate OK'd in DLBCL

Journal of Clinical Oncology

Monitoring of circulating tumor DNA improves early relapse detection after axicabtagene ciloleucel infusion in large B-cell lymphoma: results of a prospective multi-institutional trial

American Journal of Hematology

2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management


Treatment resistance in diffuse large B-cell lymphoma

Blood Advances

Impact of rituximab biosimilars on overall survival in diffuse large B-cell lymphoma: a Dutch population-based study


Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma


Male and female fertility: Prevention and monitoring Hodgkin’ lymphoma and diffuse large B-cell lymphoma adult survivors. A systematic review by the Fondazione Italiana Linfomi

Journal of Clinical Oncology

Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective Elderly Project of the Fondazione Italiana Linfomi

British Journal of Haematology

Age is the most important predictor of survival in diffuse large B-cell lymphoma patients achieving event-free survival at 24 months: a Swedish population-based study

Journal of Clinical Oncology

Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial